» Articles » PMID: 33532655

The Controversial Role of Glucose in the Diabetic Kidney

Overview
Journal Porto Biomed J
Publisher Wolters Kluwer
Date 2021 Feb 3
PMID 33532655
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The kidneys play an important role in maintaining glucose homeostasis being the main mechanisms, the gluconeogenesis, renal glucose consumption and glucose reabsorption in the proximal tubules. In this review, we present the main research into the role of glycogen-the stored form of glucose, and how it accumulates in the cells, providing new information on the link between diabetes and diabetic kidney disease. In the last 10 years, research under the scope of renal insulin handling, glucose transport in the proximal tubules, renal gluconeogenesis and renal insulin resistance, made possible to relate the roles of glucose and glycogen in the kidney with other several organs, like the liver. On the one hand, insulin positively regulates kidney uptake and degradation, and there is probably a specific action and resistance to insulin at the renal site. Moreover, insulin regulates the bioavailability of the sodium-glucose co-transporters-SGLT2 inhibitor, and inhibits renal gluconeogenesis. Only the liver and kidneys can supply glucose to the circulation through the process of gluconeogenesis, which involves the synthesis of glucose again from non-glycemic substrates; and the decomposition of stored glycogen. In the mind of nephrologists, diabetologists and scientists, glucose metabolism in the kidney is the focus, with the relevant success of inhibitors in reducing kidney and cardiovascular diseases in individuals with diabetes. However, these new data led to the intriguing paradigm that many of the beneficial effects on the renal and cardiovascular system appear to be independent of the systemic glucose-lowering actions of these agents. The goal of this work puts in context a highly relevant research area for renal glucose metabolism, of glycogen accumulation and metabolism in the diabetic kidney.

Citing Articles

Integrating transcriptomics, metabolomics, and network pharmacology to investigate multi-target effects of sporoderm-broken spores of on improving HFD-induced diabetic nephropathy rats.

Hu L, Yu L, Cao Z, Wang Y, Zhu C, Li Y J Pharm Anal. 2025; 14(12):101105.

PMID: 39840400 PMC: 11750267. DOI: 10.1016/j.jpha.2024.101105.


Renal Inflammation, Oxidative Stress, and Metabolic Abnormalities During the Initial Stages of Hypertension in Spontaneously Hypertensive Rats.

Wojtacha P, Bogdanska-Chomczyk E, Majewski M, Obremski K, Majewski M, Kozlowska A Cells. 2024; 13(21.

PMID: 39513878 PMC: 11545559. DOI: 10.3390/cells13211771.


Roles and crosstalks of macrophages in diabetic nephropathy.

Li H, You Y, Shao B, Wu W, Wang Y, Guo J Front Immunol. 2022; 13:1015142.

PMID: 36405700 PMC: 9666695. DOI: 10.3389/fimmu.2022.1015142.


Machine Learning and In Vitro Chemical Screening of Potential α-Amylase and α-Glucosidase Inhibitors from Thai Indigenous Plants.

Srisongkram T, Waithong S, Thitimetharoch T, Weerapreeyakul N Nutrients. 2022; 14(2).

PMID: 35057448 PMC: 8781461. DOI: 10.3390/nu14020267.


The Impact of the Nephrotoxin Ochratoxin A on Human Renal Cells Studied by a Novel Co-Culture Model Is Influenced by the Presence of Fibroblasts.

Schwerdt G, Kopf M, Gekle M Toxins (Basel). 2021; 13(3).

PMID: 33803529 PMC: 8003035. DOI: 10.3390/toxins13030219.

References
1.
Bornfeldt K, Tabas I . Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011; 14(5):575-85. PMC: 3217209. DOI: 10.1016/j.cmet.2011.07.015. View

2.
Kelly L, Almutairi M, Kursan S, Pacheco R, Dias-Junior E, Castrop H . Impaired glucose tolerance, glucagon, and insulin responses in mice lacking the loop diuretic-sensitive transporter. Am J Physiol Cell Physiol. 2019; 317(4):C843-C856. PMC: 6850998. DOI: 10.1152/ajpcell.00144.2019. View

3.
Pereira-Moreira R, Muscelli E . Effect of Insulin on Proximal Tubules Handling of Glucose: A Systematic Review. J Diabetes Res. 2020; 2020:8492467. PMC: 7180501. DOI: 10.1155/2020/8492467. View

4.
Liu B, Wang Y, Zhang Y, Yan B . Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Curr Top Med Chem. 2019; 19(20):1818-1849. DOI: 10.2174/1568026619666190828161409. View

5.
Cheng Z, Tseng Y, White M . Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab. 2010; 21(10):589-98. PMC: 3994704. DOI: 10.1016/j.tem.2010.06.005. View